Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc. (MTNB)
Filing Type: Form 8-K (Current Report)
Date of Report: May 14, 2019
Reporting Period: Quarter ended March 31, 2019
Status: Emerging Growth Company (Elected not to use extended transition period for new accounting standards)
Key Financial Metrics
The provided Form 8-K text serves as a notification of the release of financial results but does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. The filing states that the full text of the press release containing these metrics is furnished as Exhibit 99.1 and incorporated by reference. Therefore, specific financial values are not available in the source text provided.
Material Changes
The filing does not detail specific material changes versus the prior comparable period within the body text. It references the issuance of a press release on May 14, 2019, which contains the operational and financial results for the quarter ended March 31, 2019.
Guidance, Outlook, and Risks
The filing text does not provide specific guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the referenced press release (Exhibit 99.1) which is not included in the input text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 14, 2019) for specific Q1 2019 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the referenced exhibit.
- Check for any new debt covenants or liquidity events disclosed in the full financial results.